EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
3.310
-0.310 (-8.56%)
At close: Sep 28, 2026, 4:00 PM EDT
3.335
+0.025 (0.76%)
After-hours: Sep 28, 2026, 7:46 PM EDT
EyePoint Revenue
EyePoint had revenue of $507.00K in the quarter ending June 30, 2026, a decrease of -90.49%. This brings the company's revenue in the last twelve months to $2.79M, down -94.63% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%.
Revenue (ttm)
$2.79M
Revenue Growth
-94.63%
P/S Ratio
102.35
Revenue / Employee
$13,028
Employees
214
Market Cap
285.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Century Therapeutics | 109.16M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Evommune | 10.00M |
| Upstream Bio | 3.16M |
| SAB Biotherapeutics | 114.70K |
EYPT News
- 7 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 12 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - EyePoint Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 18 days ago - EyePoint Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 19 days ago - EyePoint Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 19 days ago - EyePoint Slides: Corporate presentation - Filings
- 26 days ago - EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewsWire
- 26 days ago - EyePoint downgraded to Hold from Buy at TD Cowen - TheFly